Literature DB >> 7160048

Protein binding of anthraquinone glycosides, with special reference to adriamycin.

S Eksborg, H Ehrsson, B Ekqvist.   

Abstract

The binding of anthraquinone glycosides (adriamycin, adriamycinol, daunorubicin, daunorubicinol, and 4'epiadriamycin) to human serum albumin and human plasma has been studied by equilibrium dialysis. About 62% of adriamycin was bound to human serum albumin (45 g/l). Only minor variations in the degree of binding were observed between the anthraquinone glycosides. The binding degree of adriamycin in plasma from cancer patients was not significantly different from that observed in healthy volunteers, the fraction of free adriamycin being 24.56% +/- 4.51%, and 27.67% +/- 2.78%, respectively. The plasma albumin concentration was significantly lower in cancer patients than in the healthy volunteers (26.90% +/- 5.88% and 39.24% +/- 1.74%, respectively). In cancer patients the fraction of free adriamycin decreased with increasing plasma albumin concentration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7160048     DOI: 10.1007/bf00257228

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  The effect of neoplastic and allied diseases on the concentrations of the plasma proteins.

Authors:  G B MIDER; E L ALLING; J J MORTON
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

2.  Binding of psychotropic drugs to isolated alpha-acid glycoprotein.

Authors:  M L Kornguth; L G Hutchins; B S Eichelman
Journal:  Biochem Pharmacol       Date:  1981-09-01       Impact factor: 5.858

3.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

Review 4.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

5.  Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.

Authors:  K K Chan; R T Chlebowski; M Tong; H S Chen; J F Gross; J R Bateman
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

6.  Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate.

Authors:  O Borgå; K M Piafsky; O G Nilsen
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

7.  Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma.

Authors:  L F Chio; C J Oon
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

8.  The protein binding of methotrexate in the serum of patients with neoplastic disease.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

9.  Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation.

Authors:  R Brodersen
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

10.  Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.

Authors:  R T Chlebowski; K K Chan; M J Tong; J M Weiner; V M Ryden; J R Bateman
Journal:  Cancer       Date:  1981-09-01       Impact factor: 6.860

View more
  11 in total

1.  The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats.

Authors:  K S Hall; L Endresen; L Schjerven; H E Rugstad
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models.

Authors:  P Bacha; S Forte; N Kassam; J Thomas; D Akiyoshi; C Waters; J Nichols; M Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Tuning the In Vivo Transport of Anticancer Drugs Using Renal-Clearable Gold Nanoparticles.

Authors:  Chuanqi Peng; Jing Xu; Mengxiao Yu; Xuhui Ning; Yingyu Huang; Bujie Du; Elizabeth Hernandez; Payal Kapur; Jer-Tsong Hsieh; Jie Zheng
Journal:  Angew Chem Int Ed Engl       Date:  2019-05-14       Impact factor: 15.336

4.  Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.

Authors:  S Eksborg; B J Cedermark; H S Strandler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

5.  Initial and early effects of adriamycin in murine sarcoma 180 cannot be restored in a resistant subline by increasing the uptake and external concentration of the drug.

Authors:  J Sonka; U Schossig; M Vogt-Schaden; M Volm
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  CE-LIF method for the separation of anthracyclines: application to protein binding analysis in plasma using ultrafiltration.

Authors:  Gillian Whitaker; Amy Lillquist; Stephanie A Pasas; Robert O'Connor; Fiona Regan; Craig E Lunte; Malcolm R Smyth
Journal:  J Sep Sci       Date:  2008-06       Impact factor: 3.645

8.  Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.

Authors:  H J Haisma; M van Muijen; H M Pinedo; E Boven
Journal:  Cell Biophys       Date:  1994

9.  Pharmacokinetics of doxorubicin in pregnant women.

Authors:  Rachel J Ryu; Sara Eyal; Henry G Kaplan; Arezoo Akbarzadeh; Karen Hays; Kristin Puhl; Thomas R Easterling; Stacey L Berg; Kathleen A Scorsone; Eric M Feldman; Jason G Umans; Menachem Miodovnik; Mary F Hebert
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-15       Impact factor: 3.333

10.  Decreased autolysis of dead cells in adriamycin-resistant lines of the sarcoma 180 of mouse.

Authors:  J Sonka; A Günther; M Volm
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.